Volition introduces nu.q® cancer blood test in new industry primer for lung cancer

"lung cancer: hope of a brighter tomorrow" illustrates how nu.q® cancer test aims to transform the diagnosis, treatment and monitoring in the $4 billion lung cancer market1 henderson, nev. , march 20, 2025 /prnewswire/ -- volitionrx limited (nyse american: vnrx) ("volition"), a multi-national epigenetics company, today announces the release of volition's new lung cancer primer, "lung cancer: hope of a brighter tomorrow.
VNRX Ratings Summary
VNRX Quant Ranking